Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (102) 102
female (86) 86
male (86) 86
middle aged (78) 78
adult (75) 75
index medicus (73) 73
hepatitis c, chronic - drug therapy (58) 58
hepacivirus - genetics (53) 53
antiviral agents - therapeutic use (51) 51
gastroenterology & hepatology (50) 50
genotype (50) 50
aged (49) 49
treatment outcome (48) 48
drug therapy, combination (45) 45
hepatitis c (39) 39
ribavirin (36) 36
interferon-alpha - therapeutic use (34) 34
antiviral agents - adverse effects (33) 33
ribavirin - therapeutic use (33) 33
hepatitis c, chronic - virology (30) 30
polyethylene glycols - therapeutic use (29) 29
hepatitis c virus (28) 28
antiviral agents - administration & dosage (27) 27
gastroenterology and hepatology (27) 27
recombinant proteins (27) 27
young adult (27) 27
double-blind method (26) 26
viral load (26) 26
interferon (24) 24
care and treatment (23) 23
plus ribavirin (23) 23
ribavirin - administration & dosage (23) 23
ribavirin - adverse effects (23) 23
rna, viral - blood (23) 23
abridged index medicus (21) 21
adolescent (21) 21
interferon-alpha - administration & dosage (21) 21
hepacivirus - drug effects (19) 19
hepatitis c - drug therapy (19) 19
interferon-alpha - adverse effects (19) 19
polyethylene glycols - administration & dosage (19) 19
telaprevir (18) 18
therapy (18) 18
virus-infection (18) 18
chronic hepatitis-c (17) 17
health aspects (17) 17
hepatitis (17) 17
biological response modifiers (16) 16
hiv (16) 16
dose-response relationship, drug (15) 15
polyethylene glycols - adverse effects (15) 15
antiviral agents (14) 14
genetic aspects (14) 14
hiv infections - complications (14) 14
recombinant proteins - therapeutic use (14) 14
sofosbuvir (14) 14
hcv (13) 13
hepatitis c, chronic - complications (13) 13
medicine, general & internal (13) 13
pharmacology & pharmacy (13) 13
combination therapy (12) 12
drug administration schedule (12) 12
drug therapy (12) 12
genotype & phenotype (12) 12
logistic models (12) 12
boceprevir (11) 11
cirrhosis (11) 11
infectious diseases (11) 11
liver cirrhosis (11) 11
recombinant proteins - administration & dosage (11) 11
uridine monophosphate - analogs & derivatives (11) 11
antiviral agents - pharmacokinetics (10) 10
combination (10) 10
hepacivirus - classification (10) 10
peginterferon alpha-2a (10) 10
sustained virological response (10) 10
antiviral therapy (9) 9
article (9) 9
chronic hepatitis c (9) 9
clinical trials (9) 9
hepatitis c, chronic - diagnosis (9) 9
hiv infections - drug therapy (9) 9
infection (9) 9
liver - pathology (9) 9
protease inhibitors (9) 9
research (9) 9
rna (9) 9
uridine monophosphate - therapeutic use (9) 9
viral nonstructural proteins - antagonists & inhibitors (9) 9
virology (9) 9
aged, 80 and over (8) 8
analysis (8) 8
dosage and administration (8) 8
fibrosis (8) 8
hepacivirus - isolation & purification (8) 8
hispanic americans (8) 8
human immunodeficiency virus--hiv (8) 8
insulin resistance (8) 8
liver (8) 8
prospective studies (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Treatment of HCV Infection by Targeting MicroRNA
by Janssen, Harry L.A and Reesink, Hendrik W and Lawitz, Eric J and Zeuzem, Stefan and Rodriguez-Torres, Maribel and Patel, Keyur and van der Meer, Adriaan J and Patick, Amy K and Chen, Alice and Zhou, Yi and Persson, Robert and King, Barney D and Kauppinen, Sakari and Levin, Arthur A and Hodges, Michael R
The New England Journal of Medicine, ISSN 0028-4793, 05/2013, Volume 368, Issue 18, pp. 1685 - 1694
In this phase 2 trial, an antisense oligonucleotide was tested in the treatment of chronic hepatitis C virus infection. The oligonucleotide was designed to... 
VIRUS-RNA | MIR-122 | MEDICINE, GENERAL & INTERNAL | METASTASIS | GENOTYPE | CHRONIC HEPATITIS-C | IN-VIVO | ANTAGONISM | EXPRESSION | Hepacivirus - isolation & purification | Oligonucleotides - therapeutic use | Antiviral Agents - therapeutic use | Humans | Middle Aged | Hepacivirus - genetics | Genotype | Male | MicroRNAs - metabolism | Oligonucleotides - adverse effects | RNA, Viral - blood | Binding Sites - genetics | Hepatitis C, Chronic - drug therapy | Dose-Response Relationship, Drug | Antiviral Agents - adverse effects | Injections, Subcutaneous | Adult | Female | Aged | Mutation | Hepatitis C, Chronic - genetics | MicroRNAs - chemistry | Antiviral agents | Care and treatment | MicroRNA | Research | Hepatitis C virus | Drug therapy | Health aspects | Liver diseases | Mortality | Liver | Body weight | MiRNA | Chronic infection | Antisense oligonucleotides | Genomes | Nucleic acids | Gene expression | Drug resistance | Patients | Hepatitis | Phosphorothioate | Antisense DNA | Hepatitis C | Liver cirrhosis | Genotypes | Viral infections
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
by Lawitz, Eric, Prof and Sulkowski, Mark S, Prof and Ghalib, Reem, MD and Rodriguez-Torres, Maribel, MD and Younossi, Zobair M, Prof and Corregidor, Ana, MD and DeJesus, Edwin, MD and Pearlman, Brian, Prof and Rabinovitz, Mordechai, Prof and Gitlin, Norman, MD and Lim, Joseph K, MD and Pockros, Paul J, MD and Scott, John D, MD and Fevery, Bart, MSc and Lambrecht, Tom, MSc and Ouwerkerk-Mahadevan, Sivi, PhD and Callewaert, Katleen, MSc and Symonds, William T, PharmD and Picchio, Gaston, PhD and Lindsay, Karen L, MD and Beumont, Maria, MD and Jacobson, Ira M, Prof
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9956, pp. 1756 - 1765
Summary Background Interferon-free regimens are needed to treat hepatitis C virus (HCV) infections. We investigated the efficacy of combined simeprevir and... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | TELAPREVIR | PHASE-3 TRIAL | DOUBLE-BLIND | BOCEPREVIR | HCV INFECTION | PEGINTERFERON | SVR | ALPHA 2A | Recombinant Proteins - therapeutic use | Uridine Monophosphate - administration & dosage | Simeprevir | Confidence Intervals | Follow-Up Studies | Humans | Middle Aged | Hepacivirus - genetics | Male | Reference Values | Polyethylene Glycols - therapeutic use | Dose-Response Relationship, Drug | Adult | Female | Drug Therapy, Combination | Liver Function Tests | Severity of Illness Index | Drug Administration Schedule | Risk Assessment | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - diagnosis | Hepatitis C, Chronic - drug therapy | Sulfonamides - therapeutic use | Heterocyclic Compounds, 3-Ring - therapeutic use | Uridine Monophosphate - analogs & derivatives | Hepatitis C, Chronic - genetics | Sofosbuvir | Hepatitis | Genotype & phenotype | Liver diseases | Biopsy | Infections | Drug therapy | Liver cirrhosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
by Lawitz, Eric, Prof and Lalezari, Jay P, MD and Hassanein, Tarek, Prof and Kowdley, Kris V, Prof and Poordad, Fred F, Prof and Sheikh, Aasim M, MBBS and Afdhal, Nezam H, Prof and Bernstein, David E, Prof and DeJesus, Edwin, MD and Freilich, Bradley, MD and Nelson, David R, Prof and Dieterich, Douglas T, Prof and Jacobson, Ira M, Prof and Jensen, Donald, Prof and Abrams, Gary A, MD and Darling, Jama M, MD and Rodriguez-Torres, Maribel, MD and Reddy, K Rajender, Prof and Sulkowski, Mark S, Prof and Bzowej, Natalie H, MD and Hyland, Robert H, DPhil and Mo, Hongmei, PhD and Lin, Ming, PhD and Mader, Michael, MS and Hindes, Robert, MD and Albanis, Efsevia, MD and Symonds, William T, PharmD and Berrey, Michelle M, MD and Muir, Andrew, Prof
Lancet Infectious Diseases, The, ISSN 1473-3099, 2013, Volume 13, Issue 5, pp. 401 - 408
Summary Background Protease inhibitors have improved treatment of infection with hepatitis C virus (HCV), but dosing, a low barrier to resistance, drug... 
Infectious Disease | PSI-7977 | INFECTIOUS DISEASES | PLUS RIBAVIRIN | VIRUS-INFECTION | TELAPREVIR | BOCEPREVIR | INHIBITORS | Recombinant Proteins - therapeutic use | Uridine Monophosphate - administration & dosage | Nausea - chemically induced | Humans | Middle Aged | Hepatitis C, Chronic - virology | Hepacivirus - pathogenicity | Male | Secondary Prevention | Polyethylene Glycols - therapeutic use | Young Adult | Time Factors | Ribavirin - administration & dosage | Adult | Female | Headache - chemically induced | Uridine Monophosphate - therapeutic use | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | RNA, Viral - analysis | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Drug Therapy, Combination - methods | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Adolescent | Liver Cirrhosis - pathology | Aged | Hepacivirus - classification | Sofosbuvir | Care and treatment | Protease inhibitors | Proteases | Gastrointestinal diseases | Clinical trials | Product development | Genetic aspects | Interferon | Hepatitis C | Health aspects | Liver cirrhosis | Viral antigens
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Multiple ascending dose study of BMS‐790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1
by Nettles, Richard E and Gao, Min and Bifano, Marc and Chung, Ellen and Persson, Anna and Marbury, Thomas C and Goldwater, Ronald and DeMicco, Michael P and Rodriguez‐Torres, Maribel and Vutikullird, Apinya and Fuentes, Ernesto and Lawitz, Eric and Lopez‐Talavera, Juan Carlos and Grasela, Dennis M
Hepatology, ISSN 0270-9139, 12/2011, Volume 54, Issue 6, pp. 1956 - 1965
The antiviral activity, resistance profile, pharmacokinetics (PK), safety, and tolerability of BMS‐790052, a nonstructural protein 5A (NS5A) replication... 
NS5A INHIBITOR | TRIAL | RATES | INTERFERON-ALPHA | TELAPREVIR | THERAPY | VX-950 | PEGINTERFERON-ALPHA-2A | RIBAVIRIN | COMBINATION | GASTROENTEROLOGY & HEPATOLOGY | Hepacivirus - drug effects | Antiviral Agents - pharmacokinetics | Double-Blind Method | Humans | Middle Aged | Half-Life | Imidazoles - administration & dosage | Male | RNA, Viral - blood | Imidazoles - pharmacokinetics | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Viral Load | Adolescent | Adult | Female | Viral Nonstructural Proteins - antagonists & inhibitors | Hepatitis | Genotype & phenotype | Human immunodeficiency virus--HIV
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Contribution of common genetic variation to the risk of type 2 diabetes in the Mexican Mestizo population
by Gamboa-Meléndez, Marco Alberto and Huerta-Chagoya, Alicia and Moreno-Macías, Hortensia and Vázquez-Cárdenas, Paola and Ordóñez-Sánchez, María Luisa and Rodríguez-Guillén, Rosario and Riba, Laura and Rodríguez-Torres, Maribel and Guerra-García, María Teresa and Guillén-Pineda, Luz Elizabeth and Choudhry, Shweta and Del Bosque-Plata, Laura and Canizales-Quinteros, Samuel and Pérez-Ortiz, Gustavo and Escobedo-Aguirre, Fernando and Parra, Adalberto and Lerman-Garber, Israel and Aguilar-Salinas, Carlos Alberto and Tusié-Luna, María Teresa
Diabetes, ISSN 0012-1797, 12/2012, Volume 61, Issue 12, pp. 3314 - 3321
Several studies have identified nearly 40 different type 2 diabetes susceptibility loci, mainly in European populations, but few of them have been evaluated in... 
SAMPLE | MULTILOCUS GENOTYPE DATA | REPLICATION | VARIANTS | TCF7L2 POLYMORPHISMS | SUSCEPTIBILITY | ENDOCRINOLOGY & METABOLISM | LOCI | CANDIDATE GENE | MELLITUS | GENOME-WIDE ASSOCIATION | RNA-Binding Proteins - genetics | Calcium-Calmodulin-Dependent Protein Kinase Type 1 - genetics | Genetic Predisposition to Disease - genetics | Genome-Wide Association Study | KCNQ1 Potassium Channel - genetics | Transcription Factor 7-Like 2 Protein - genetics | Zinc Transporter 8 | Diabetes Mellitus, Type 2 - genetics | Humans | Middle Aged | Genotype | Male | Transcription Factors - genetics | Homeodomain Proteins - genetics | Cyclin-Dependent Kinase 5 - genetics | Cyclin-Dependent Kinase Inhibitor p15 - genetics | tRNA Methyltransferases | Polymorphism, Single Nucleotide - genetics | Cation Transport Proteins - genetics | Female | Mexico | Type 2 diabetes | Racially mixed people | Genetic variation | Mexicans | Genetic aspects | Health aspects | Risk factors | Metabolomics | Genetics | Genomes | Proteomics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text High sustained virologic response rates in rapid virologic response patients in the large real‐world PROPHESYS cohort confirm results from randomized clinical trials
by Marcellin, Patrick and Cheinquer, Hugo and Curescu, Manuela and Dusheiko, Geoffrey M and Ferenci, Peter and Horban, Andrzej and Jensen, Donald and Lengyel, Gabriella and Mangia, Alessandra and Ouzan, Denis and Puoti, Massimo and Rodriguez‐Torres, Maribel and Shiffman, Mitchell L and Schmitz, Manuela and Tatsch, Fernando and Rizzetto, Mario
Hepatology, ISSN 0270-9139, 12/2012, Volume 56, Issue 6, pp. 2039 - 2050
The ability to predict which patients are most likely to achieve a sustained virologic response (SVR) with peginterferon/ribavirin would be useful in... 
GENETIC-VARIATION | TREATMENT DURATION | VIRUS-INFECTION | PEGINTERFERON ALPHA-2A | NAIVE PATIENTS | CHRONIC HEPATITIS-C | INTERFERON-ALPHA-2B PLUS RIBAVIRIN | PEGYLATED INTERFERON | GENOTYPE 1 INFECTION | COMBINATION | GASTROENTEROLOGY & HEPATOLOGY | Recombinant Proteins - therapeutic use | Interferon-alpha - pharmacology | Predictive Value of Tests | Prospective Studies | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | RNA, Viral - blood | Polyethylene Glycols - therapeutic use | Time Factors | Adult | Female | Drug Therapy, Combination | Polyethylene Glycols - pharmacology | Antiviral Agents - pharmacology | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Logistic Models | Biomarkers - blood | Recombinant Proteins - pharmacology | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - blood | Randomized Controlled Trials as Topic | Aged | Viral Load - drug effects | Ribavirin - pharmacology | Confidence intervals | Hepatitis | Genotype & phenotype | Human immunodeficiency virus--HIV | Hepatology | Interferon | Drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection
by Rodríguez-Torres, Maribel
Expert Review of Anti-Infective Therapy, ISSN 1478-7210, 2013, Volume 11, Issue 12, pp. 1269 - 1279
Given the global importance of chronic HCV infection as a major health burden, there is still a need for developing treatment options that are more efficient,... 
Nucleotide analogue | Direct-acting antiviral | Chronic hepatitis C | UNITED-STATES | PLUS RIBAVIRIN | chronic hepatitis C | nucleotide analogue | COMBINATION | direct-acting antiviral | PEGINTERFERON ALPHA-2A | CIRRHOSIS | PHARMACOLOGY & PHARMACY | UPDATE | BURDEN | TREATMENT-NAIVE PATIENTS | PHASE-2 TRIAL | Hepacivirus - drug effects | Recombinant Proteins - therapeutic use | Antiviral Agents - therapeutic use | Humans | Ribavirin - therapeutic use | Biomarkers, Pharmacological | Interferon-alpha - therapeutic use | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Genotype | Treatment Outcome | Clinical Trials as Topic | Hepatitis C, Chronic - drug therapy | Polyethylene Glycols - therapeutic use | Drug Synergism | Uridine Monophosphate - analogs & derivatives | Hepacivirus - growth & development | Drug Therapy, Combination | Sofosbuvir | Uridine Monophosphate - therapeutic use
Journal Article
Details down arrow
8. Full Text Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
by Jacobson, Ira M and Gordon, Stuart C and Kowdley, Kris V and Yoshida, Eric M and Rodriguez-Torres, Maribel and Sulkowski, Mark S and Shiffman, Mitchell L and Lawitz, Eric and Everson, Gregory and Bennett, Michael and Schiff, Eugene and Al-Assi, M. Tarek and Subramanian, G. Mani and An, Di and Lin, Ming and McNally, John and Brainard, Diana and Symonds, William T and McHutchison, John G and Patel, Keyur and Feld, Jordan and Pianko, Stephen and Nelson, David R and POSITRON Study and FUSION Study
The New England Journal of Medicine, ISSN 0028-4793, 05/2013, Volume 368, Issue 20, pp. 1867 - 1877
In two randomized trials, the oral nucleotide polymerase inhibitor sofosbuvir combined with ribavirin for 12 or 16 weeks was effective in patients with chronic... 
MEDICINE, GENERAL & INTERNAL | PLUS RIBAVIRIN | MANAGEMENT | Antiviral Agents - therapeutic use | Humans | Middle Aged | Ribavirin - therapeutic use | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Genotype | Logistic Models | Male | RNA, Viral - blood | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Young Adult | Liver Cirrhosis - virology | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Adult | Female | Aged | Uridine Monophosphate - adverse effects | Drug Therapy, Combination | Sofosbuvir | Uridine Monophosphate - therapeutic use | Antiviral agents | Care and treatment | Causes of | Dosage and administration | Research | Hepatitis C | Mental illness | Headache | Clinical trials | Chronic infection | Fatigue | Infections | Nausea | Patients | Ribavirin | Cirrhosis | Sleep disorders | Genotype & phenotype | Hepatitis | Interferon | Drug therapy | Genotypes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
by Sulkowski, Mark S and Gardiner, David F and Rodriguez-Torres, Maribel and Reddy, K. Rajender and Hassanein, Tarek and Jacobson, Ira and Lawitz, Eric and Lok, Anna S and Hinestrosa, Federico and Thuluvath, Paul J and Schwartz, Howard and Nelson, David R and Everson, Gregory T and Eley, Timothy and Wind-Rotolo, Megan and Huang, Shu-Pang and Gao, Min and Hernandez, Dennis and McPhee, Fiona and Sherman, Diane and Hindes, Robert and Symonds, William and Pasquinelli, Claudio and Grasela, Dennis M and AI444040 Study Grp and AI444040 Study Group
The New England Journal of Medicine, ISSN 0028-4793, 01/2014, Volume 370, Issue 3, pp. 211 - 221
In this study, once-daily treatment with oral daclatasvir plus sofosbuvir was associated with high rates of sustained virologic response among patients with... 
GENOTYPE 1 | MEDICINE, GENERAL & INTERNAL | REPLICATION COMPLEX INHIBITOR | TELAPREVIR | PEGINTERFERON ALPHA-2A | CHRONIC HEPATITIS-C | DOUBLE-BLIND | VIRUS EPIDEMIOLOGY | RIBAVIRIN | HEALTH BURDEN | COMBINATION | Humans | Middle Aged | Hepacivirus - genetics | Male | Young Adult | Adult | Female | Uridine Monophosphate - adverse effects | Imidazoles - therapeutic use | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Uridine Monophosphate - therapeutic use | Hepacivirus - drug effects | Hepacivirus - isolation & purification | Antiviral Agents - therapeutic use | Imidazoles - adverse effects | Ribavirin - therapeutic use | RNA, Viral - analysis | Genotype | Hepatitis C, Chronic - drug therapy | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Viral Nonstructural Proteins - antagonists & inhibitors | Sofosbuvir | Care and treatment | Research | Drug therapy, Combination | Hepatitis C | Headache | Antiretroviral drugs | Mortality | Chronic infection | Fatigue | Infections | Nausea | Proteinase inhibitors | Ribonucleic acid--RNA | Patients | RNA-directed RNA polymerase | Ribavirin | Nucleotide analogs | Genotype & phenotype | Hepatitis | Human immunodeficiency virus--HIV | Genotypes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
by Lawitz, Eric and Mangia, Alessandra and Wyles, David and Rodriguez-Torres, Maribel and Hassanein, Tarek and Gordon, Stuart C and Schultz, Michael and Davis, Mitchell N and Kayali, Zeid and Reddy, K. Rajender and Jacobson, Ira M and Kowdley, Kris V and Nyberg, Lisa and Subramanian, G. Mani and Hyland, Robert H and Arterburn, Sarah and Jiang, Deyuan and McNally, John and Brainard, Diana and Symonds, William T and McHutchison, John G and Sheikh, Aasim M and Younossi, Zobair and Gane, Edward J
The New England Journal of Medicine, ISSN 0028-4793, 05/2013, Volume 368, Issue 20, pp. 1878 - 1887
In two studies of sofosbuvir for previously untreated HCV infection, patients with genotype 1, 4, 5, or 6 had a 90% rate of sustained virologic response in a... 
ALPHA-2A | MEDICINE, GENERAL & INTERNAL | PLUS RIBAVIRIN | VIRUS-INFECTION | POLYMERASE | UPDATE | PREVALENCE | Recombinant Proteins - therapeutic use | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins - adverse effects | Polyethylene Glycols - therapeutic use | Young Adult | Adult | Female | Uridine Monophosphate - adverse effects | Drug Therapy, Combination | Uridine Monophosphate - therapeutic use | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Genotype | Logistic Models | Hepatitis C, Chronic - drug therapy | Liver Cirrhosis - virology | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Interferon-alpha - adverse effects | Sofosbuvir | Antiviral agents | Complications and side effects | Causes of | Dosage and administration | Research | Hepatitis C virus | Blood diseases | Headache | Clinical trials | Chronic infection | Fatigue | Nausea | Ribavirin | Studies | Genotype & phenotype | Hepatitis | Hepatitis C | Drug therapy | Drug dosages | Genotypes | Neutropenia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights